30-Second Takeaway
- EEG-guided pediatric anesthesia substantially reduces emergence delirium and PACU time without increasing burst suppression
- Sugammadex in severe CKD shows similar short-term cardiopulmonary and mortality outcomes to neostigmine after GI surgery
- Dexmedetomidine blunts remifentanil-associated hyperalgesia and opioid use but increases intraoperative bradycardia
- Thoracic epidural placement fails frequently in older and obese patients—plan backup regional or analgesic strategies
- Desflurane speeds early recovery but increases PONV versus propofol in ambulatory surgery
Week ending February 7, 2026
Brain- and patient-centered anesthesia: EEG depth, reversal choices, regional reliability, and recovery experience
EEG-guided pediatric anesthesia reduces emergence delirium and PACU stay
This meta-analysis of 9 RCTs included 1052 children aged 1–18 years undergoing general anesthesia. EEG-guided anesthesia reduced emergence delirium from 48% to 27% (RR 0.56; 95% CI 0.37–0.84). EEG guidance also lowered maximum emergence delirium scores, end-tidal sevoflurane concentrations, and PACU length of stay. Burst suppression episodes were similar between groups, suggesting brain monitoring benefits without more isoelectric EEG. Findings support integrating EEG guidance into pediatric sevoflurane anesthetics to lessen maladaptive emergence behaviors.
Sugammadex versus neostigmine in severe CKD shows similar safety
This retrospective propensity-matched cohort used a US multi-institutional database of adults with severe CKD undergoing elective gastrointestinal surgery. After 1:1 matching, 5690 patients per group received either sugammadex or neostigmine for rocuronium reversal. At 30 days, composite pulmonary complications, acute respiratory failure, and major adverse cardiovascular events were similar between groups. ICU admissions were slightly higher with sugammadex but not significant after Bonferroni correction, and mortality did not differ at 7, 30, or 90 days. Sugammadex was not associated with increased pulmonary, cardiovascular, or mortality risk, though unmeasured confounding remains possible.
Dexmedetomidine attenuates remifentanil hyperalgesia and opioid use
This systematic review and meta-analysis synthesized 13 RCTs including 803 adult surgical patients receiving remifentanil-based anesthesia. Intravenous dexmedetomidine prolonged time to first rescue analgesia by about 46 minutes compared with controls. It reduced postoperative opioid consumption in PACU and at 24 hours and lowered pain scores during the first postoperative day. Dexmedetomidine conferred a moderate protective effect against primary hyperalgesia but increased intraoperative bradycardia. Use dexmedetomidine as a remifentanil adjunct with vigilant hemodynamic monitoring and individualized dosing.
Single 4 mg intranasal naloxone rapidly restores ventilation
This prospective crossover trial studied 12 opioid-naïve and 18 daily opioid users receiving fentanyl or sufentanil infusions titrated to 30–40% ventilation reduction. A single 4 mg intranasal naloxone dose restored minute ventilation within 2–4 minutes in all participants. End-tidal CO₂ normalized more slowly, over 11–17 minutes, and often incompletely during sufentanil exposure. Withdrawal symptoms limited repeat participation in many daily opioid users, highlighting tolerability issues. Findings support rapid clinical utility of intranasal naloxone while underscoring the need for prolonged monitoring and possible redosing with potent opioids.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.